Gilead Sciences | GILD - Current Assets

Stock Price
130.40
Daily Change
-3.24 -2.42%
Monthly
-5.68%
Yearly
26.39%
Q2 Forecast
127.61

Gilead Sciences reported $19.89B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
J&J USD 59.17B 3.55B Mar/2026
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
United Therapeutics USD 3.7B 208.5M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025